These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 25249260)

  • 1. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
    Liu YR; Jiang YZ; Yu KD; Shao ZM
    Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
    Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
    Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.
    Grann VR; Troxel AB; Zojwalla NJ; Jacobson JS; Hershman D; Neugut AI
    Cancer; 2005 Jun; 103(11):2241-51. PubMed ID: 15844176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
    Zheng YZ; Wang L; Hu X; Shao ZM
    Oncotarget; 2015 Sep; 6(26):22985-95. PubMed ID: 26036636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
    Yu KD; Wu J; Shen ZZ; Shao ZM
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2201-9. PubMed ID: 22993034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis.
    Cai S; Zuo W; Lu X; Gou Z; Zhou Y; Liu P; Pan Y; Chen S
    Front Oncol; 2020; 10():1729. PubMed ID: 33072554
    [No Abstract]   [Full Text] [Related]  

  • 8. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
    Hanrahan EO; Gonzalez-Angulo AM; Giordano SH; Rouzier R; Broglio KR; Hortobagyi GN; Valero V
    J Clin Oncol; 2007 Nov; 25(31):4952-60. PubMed ID: 17971593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.
    Zaky SS; Lund M; May KA; Godette KD; Beitler JJ; Holmes LR; O'Regan RM; Yu ES; Yu DS; Landry JC
    Ann Surg Oncol; 2011 Oct; 18(10):2858-65. PubMed ID: 21442346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is conservative surgery a good option for patients with "triple negative" breast cancer?
    Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
    Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone receptor status may impact the survival benefit of surgery in stage iv breast cancer: a population-based study.
    Tan Y; Li X; Chen H; Hu Y; Jiang M; Fu J; Yuan Y; Ding K
    Oncotarget; 2016 Oct; 7(43):70991-71000. PubMed ID: 27542240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
    Wang C; Zhou Y; Zhu H; Huang W; Chen Z; Mao F; Lin Y; Zhang X; Shen S; Zhong Y; Li Y; Sun Q
    Cancer Med; 2018 Nov; 7(11):5420-5430. PubMed ID: 30277006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer.
    Yu J; Gao F; Klimberg VS; Margenthaler JA
    Ann Surg Oncol; 2012 Oct; 19(10):3159-64. PubMed ID: 22878611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study.
    Leone JP; Leone J; Zwenger AO; Vallejo CT; Leone BA
    Am J Clin Oncol; 2019 Jul; 42(7):588-595. PubMed ID: 31166208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
    Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W;
    J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
    Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
    BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast-Conserving Therapy Versus Mastectomy in Young Breast Cancer Patients Concerning Molecular Subtypes: A SEER Population-Based Study.
    Yu P; Tang H; Zou Y; Liu P; Tian W; Zhang K; Xie X; Ye F
    Cancer Control; 2020; 27(1):1073274820976667. PubMed ID: 33356518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups.
    Zheng H; Ge C; Lin H; Zhou S; Tang W; Wang Q; Zhang X; Jin X; Xu X; Du J; Fu J
    PLoS One; 2023; 18(1):e0280474. PubMed ID: 36652446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.